STAT+: Pharmalittle: We’re reading about a Parkinson’s drug setback, a Merck lung cancer therapy, and more

<iframe
  src="https://statesidedaily.com/embed/cluster/b915c3e8af3050a9f4b8a3359383e20fd3e90929"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="STAT+: Pharmalittle: We&#8217;re reading about a Parkinson&#8217;s drug setback, a Merck lung cancer therapy, and more"></iframe>